ミッション
At EVerMed, we advance high-impact EV therapeutics while building the core platform needed to industrialize both natural and engineered EV medicines.
“Creating Future Therapies with the Extracellular Vesicle Platform
For Patients with Respiratory Disease”
Leveraging the multifaceted effects and superior delivery of EVs, we further enhance their functions through engineering.
Our platform combines the natural pharmacological synergy of EVs with advanced engineering to overcome conventional delivery limits. By enhancing their innate efficiency and tissue specificity, we maximize therapeutic potency while minimizing systemic side effects.
The Three Strategic Pillars of Our Modality. At EVerMed, we believe Extracellular Vesicles (EVs) represent the most sophisticated delivery and therapeutic system ever engineered—by nature itself. Here is why we focus on EVs over conventional modalities.
Unlike synthetic “bubble” nanocarriers such as lipid nanoparticles (LNPs), EVs are naturally occurring, pre-assembled biological carriers informed by the human body.
The most significant advantage of EVs is their ability to act as a multi-functional modality. Complex Cargo Delivery. Unlike traditional single-agent drugs, EVs naturally carry a diverse cocktail of RNAs, proteins and lipids encoded by their cell of origin.
A Multi-Targeting Tool. This inherent multi-functionality allows EVs to address complex pathologies through multiple therapeutic mechanisms.
Research increasingly shows that the therapeutic benefits of cell therapy are often driven not by the cells themselves, but by the factors they secrete — a paracrine effect.
Replacing Cells with Biologics. Since EVs are the primary mediators of these paracrine effects, they can effectively replace whole-cell therapies in many clinical applications.
EVerMed is led by internationally recognized experts in extracellular vesicle biology, translational research, and pharmaceutical strategy.
Our team combines deep academic excellence with extensive industry experience in drug development and regenerative medicine.
This integrated leadership structure enables us to bridge fundamental science with clinical and commercial realization.
We actively collaborate with academic institutions, pharmaceutical and biotechnology companies, and strategic capital partners to advance the frontier of EV therapeutics.
Through joint research, pipeline licensing, and co-development initiatives, we aim to accelerate translation from mechanistic discovery to clinical application.
Together, we seek to build a sustainable ecosystem for next-generation EV medicine.
Examples of Inquiries